|
Synonyms: BLA 761046 | MBL-CDB1 | MDX-1388 | Zinplava®
bezlotoxumab is an approved drug (FDA (2016), EMA (2017), Japan (2017))
Compound class:
Antibody
Comment: Bezlotoxumab is a fully human IgG1 monoclonal antibody that binds to Clostridioides difficile toxin B [1]. It does not have inherent antibacterial activity but prevents binding of toxin B to colonic cells and reducing colonic cell inflammation. It is used to reduce the recurrence of C. difficile infection (CDI) in patients receiving antibacterial treatment for CDI.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| Bezlotoxumab is administered by intravenous infusion. |
| External links |
|
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |
